METAVIA INC. Long-Term Debt, Maturity, Year Two
METAVIA INC. (MTVA) had Long-Term Debt, Maturity, Year Two of $4.81 million as of 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2018-11-08
- 2018-09-30: Long-Term Debt, Maturity, Year Two $4.81M.
- 2018-06-30: Long-Term Debt, Maturity, Year Two $4.79M.
- 2018-03-31: Long-Term Debt, Maturity, Year Two $4.30M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2018-09-30 | $4.81M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $4.79M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $4.30M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |